English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In their article published in this issue of The Journal of Nuclear Medicine (1), Hillner and coauthors once again emerge from the trove of data that is the National Oncologic PET Registry (NOPR) with valuable insights. This time, the investigators turned their attention to 7 cancers, plus a hodgepodge of rare tumors, for which Medicare still does not cover the use of PET for restaging or suspected recurrence or for evaluating patients’ response to treatment, except for PET facilities participating in Medicare’s coverage-with-evidence-development (CED) program. The principal finding of Hillner et al. is that, in comparing data accrued during 2006–2009

A Broader Importance of NOPR to the Future of Nuclear Imaging